𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia

✍ Scribed by Neil E. Kay; Wenting Wu; Brian Kabat; Betsy LaPlant; Thomas S. Lin; John C. Byrd; Diane F. Jelinek; Michael R. Grever; Clive S. Zent; Timothy G. Call; Tait D. Shanafelt

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
164 KB
Volume
116
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Pentostatin, cyclophosphamide, and ritux
Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia
✍ Tait D. Shanafelt; Thomas Lin; Susan M. Geyer; Clive S. Zent; Nelson Leung; Bria πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 142 KB πŸ‘ 1 views

## Abstract ## BACKGROUND. The prevalence of chronic lymphocytic leukemia (CLL) increases with age. Although chemoimmunotherapy (CIT) has dramatically improved response rates in patients with CLL, some CIT regimens are not well tolerated by many patients β‰₯70 years of age. ## METHODS. Sixty‐four

Thalidomide and dexamethasone therapy of
Thalidomide and dexamethasone therapy of myeloma in a patient with previously untreated B-chronic lymphocytic leukemia
✍ James C. Barton πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 68 KB πŸ‘ 2 views

## Abstract A 67‐year‐old woman with previously untreated lambda‐positive B‐chronic lymphocytic leukemia (CLL) had kappa‐positive myeloma develop that was treated with daily thalidomide and intermittent dexamethasone. After 4 months, there was a marked reduction in marrow plasmacytosis, urine kappa

Consolidation and maintenance immunother
Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia
✍ Giovanni Del Poeta; Maria Ilaria Del Principe; Francesco Buccisano; Luca Maurill πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 186 KB πŸ‘ 1 views

## Abstract ## BACKGROUND. Rituximab in sequential combination with fludarabine (Flu) allowed patients with B‐cell chronic lymphocytic leukemia (B‐CLL) to achieve higher remission rates and longer response duration. Based on their recent experience in indolent non‐Hodgkin lymphomas, in this study,

High rate of centrosome aberrations and
High rate of centrosome aberrations and correlation with proliferative activity in patients with untreated B-cell chronic lymphocytic leukemia
✍ Manfred Hensel; Martin Zoz; Christian Giesecke; Axel Benner; Kai Neben; Anna Jau πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 French βš– 138 KB πŸ‘ 1 views

## Abstract B‐cell chronic lymphocytic leukemia (CLL) is characterized by a high rate of clonal genomic alterations and a low proliferative activity with cell cycle arrest in G~0~/G~1~ phase. Recently, centrosome aberrations have been described as a possible cause of chromosomal instability and ane